Meeting a key secondary endpoint, more patients on obinutuzumab achieved a complete renal response with a prednisone taper to 7.5 mg/day or lower between weeks 64 and 76 (42.7% vs 30.9% ...

As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

Obinutuzumab B-cell depleting therapy is more effective than standard care in treating patients with active proliferative lupus nephritis.

As a result, there is no evidence from controlled studies on the efficacy of different initial doses or drug tapering. The only controlled study suggests that initial prednisone doses ≤ 10 mg is ...

Key secondary endpoints included the proportion of people who achieved CRR at week 76 with successful reduction of corticosteroid use (prednisone taper); the proportion who achieved proteinuric ...

A phase 2 study evaluated the use of ruxolitinib plus standard GVHD prophylaxis in patients with myelofibrosis undergoing ...

The data, which so far have been presented only in abstract form, suggest that budesonide is efficient in inducing stable remission, is superior compared with a standard prednisone-tapering ...

Dr. Lu-Culligan: The patient completed the tapering prednisone course in 7 weeks, with resolution of the musculoskeletal pain and rash, along with normalization of the erythrocyte sedimentation ...

Gazyva/Gazyvaro (obinutuzumab) was found to significantly improve complete renal response in lupus nephritis patients, reinforcing its potential as an effective treatment option while also allowing ...

Pedraza-Cruz, P. , Varghese, M. , DiGiacomo, D. , Spencer, C. and Horani, O. (2025) Adrenal Crisis Secondary to Bilateral ...

Prednisone is commonly prescribed, with an initial high-dose regimen of 1 mg/kg/day (up to 80 mg/day), followed by a gradual taper based on clinical response and biochemical markers such as ...